Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/heartjnl-2013-304902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin.
J Lipid Res
December 2024
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA 46285. Electronic address:
Article Synopsis
- * Current tests for measuring Lp(a) often assess total apo(a), which may not accurately reflect Lp(a) levels or the effects of new treatments.
- * A new immunoassay developed for measuring Lp(a) particles showed better accuracy, indicating that muvalaplin's Lp(a)-lowering effects were previously underestimated by commercial tests, while lepodisiran's effects were consistent across both methods.
Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.
Lipids Health Dis
September 2024
Université Claude Bernard Lyon 1, University College of General Medicine, 8 Avenue Rockefeller, Lyon, 69008, France.
Background: Retention of apolipoprotein B (apoB)-containing lipoproteins within the arterial wall plays a major causal role in atherosclerotic cardiovascular disease (ASCVD). There is a single apoB molecule in all apoB-containing lipoproteins. Therefore, quantitation of apoB directly estimates the number of atherogenic particles in plasma.
View Article and Find Full Text PDFPrevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease.
J Clin Lipidol
December 2023
Hartford Healthcare, Hartford, CT (Drs Panza, Tortora, Saucier, Fernandez). Electronic address:
Introduction: Lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease. Despite recommendations from professional societies in the cardiovascular field, the awareness of elevated Lp(a) as a risk factor and screening for Lp(a) are suspected to be low.
Methods: We conducted a retrospective, observational case control study of patient charts from January 1, 2017 to June 19, 2022.
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
Atherosclerosis
June 2023
Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, and IRCCS MultiMedica, Milan, Italy.
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development.
View Article and Find Full Text PDFQuantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
Cardiovasc Drugs Ther
February 2024
Medpace Reference Laboratories, Cincinnati, OH, USA.
Purpose: Cholesterol in lipoprotein(a) [Lp(a)-C] is commonly estimated as 30% of the measured Lp(a) mass. However, difficulties in the accurate measurement of Lp(a) mass, along with the inaccuracy of the 30% assumption, produce erroneous values when LDL-C is corrected for Lp(a) [LDL-C]. Our aim was to develop a new formula for LDL-C to reduce this error.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!